Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agios, Celgene Target Accelerated Approvals For Precision AML Medicines

Executive Summary

Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.

Advertisement

Related Content

Celgene, Agios Ready For Enasidenib Launch After Early Approval
2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
It's Not All About IO: Seven Drugs To Watch At ASCO
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
Agios Gets $200m Up Front In New Celgene Deal, Regains AG-120 Rights
ASH 2015: First-In-Class Myeloma Highlights
Celgene, Agios extend collaboration as AG-221 impresses at ASH 2014
BioNotebook: Emergent/Cangene, Sprout, Agios/Celgene, Sutro, Savient/Crealta
Agios gains $20M to extend April cancer deal with Celgene
Celgene and Agios to target cancer metabolism in $250 million deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel